Pinnbrook Capital Management LP Buys New Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Pinnbrook Capital Management LP purchased a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 225,320 shares of the company’s stock, valued at approximately $4,966,000.

A number of other large investors also recently modified their holdings of the business. Smithfield Trust Co raised its holdings in Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after acquiring an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $50,000. Claro Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $52,000. Venturi Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at $60,000. Finally, Ameliora Wealth Management Ltd. acquired a new position in Teva Pharmaceutical Industries during the fourth quarter worth $66,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is owned by insiders.

Teva Pharmaceutical Industries Trading Down 2.4 %

Teva Pharmaceutical Industries stock opened at $16.24 on Tuesday. The stock’s 50 day moving average is $19.93 and its 200-day moving average is $18.50. The company has a quick ratio of 0.61, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 12 month low of $12.51 and a 12 month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, sell-side analysts expect that Teva Pharmaceutical Industries Limited will post 2.62 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on TEVA shares. Barclays cut their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Piper Sandler upped their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. UBS Group reduced their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Finally, JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.57.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.